BeyondSpring

BeyondSpring, Inc. engages in the development and commercialization of immuno-oncology cancer therapies. It operates through the PRC and U.S. geographical segments. The company was founded by Lan Huang and Lin Qing Jia in 2010 and is headquartered in New York, NY.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BeyondSpring, Inc. engages in the development and commercialization of immuno-oncology cancer therapies. It operates through the Plinabulin Pipeline and TPD Platform segments. The Plinabulin Pipeline segment focuses on the development of cancer therapies. The TPD Platform segment engages in the development of therapeutic agents and discover chemical entities. The company was founded by Lan Huang and Lin Qing Jia in 2010 and is headquartered in Florham Park, NJ.

BeyondSpring Inc. (NASDAQ:BYSI ) Q4 2022 Earnings Conference Call April 14, 2022 8:00 AM ET Company Participants Ashley Sierchio - LifeSci Advisors Lan Huang - Co-Founder, Chairman and CEO Ramon Mohanlal - EVP, Research & Development and Chief Medical Officer Elizabeth Czerepak - CFO Conference Call Participants Maurice Raycroft - Jefferies Joel Beatty - Robert W. Baird Joseph Pantginis - H.C.

BeyondSpring Inc. (BYSI) CEO Lan Huang on Q4 2021 Results - Earnings Call Transcript

NEW YORK, April 14, 2022 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a clinical stage global biopharmaceutical company focused on developing innovative cancer therapies to improve clinical outcomes for patients who have high unmet medical needs, today announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2021 with the U.S. Securities and Exchange Commission (“SEC”) on April 14, 2022. The annual report on Form 20-F, which contains the Company's audited consolidated financial statements, can be accessed on the SEC's website at www.sec.gov and on the Company's website at www.beyondspringpharma.com under “Financials & Filings” in the Investors section.

BeyondSpring Files 2021 Annual Report on Form 20-F

- Company to host call today, April 14, 2022 at 8:00 am ET

BeyondSpring Announces Fourth Quarter and Year End 2021 Financial Results and Provides a Corporate Update

NEW YORK, April 08, 2022 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that it will report its financial results for the quarter and year ended December 31, 2021 before market open on Thursday, April 14, 2022. Management will also host a conference call with investors to discuss financial results and provide a corporate update at 8:00 am Eastern Time.

BeyondSpring to Announce Fourth Quarter and Year End 2021 Financial Results and Host a Conference Call on Thursday, April 14, 2022

BeyondSpring Inc (NASDAQ: BYSI) plans to reduce its U.S. workforce by 35%, including reassignment of certain personnel to subsidiaries, which is expected to result in cost savings that will extend the cash runway. The reorganization follows the FDA Complete Response Letter for plinabulin marketing application to prevent chemotherapy-induced neutropenia (CIN).

BeyondSpring Cuts On-Third Of Its Workforce

NEW YORK, Jan. 11, 2022 (GLOBE NEWSWIRE) -- BeyondSpring Pharmaceuticals (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global pharmaceutical company focused on the development of cancer therapeutics, today announced an organizational streamlining initiative focused on prioritizing the Company's highest value business activities, extending its cash runway and preserving long-term sustainability.

BeyondSpring Announces Organizational Streamlining

BeyondSpring Inc. (BYSI) delivered earnings and revenue surprises of 18.97% and 0.88%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

BeyondSpring Inc. (BYSI) Reports Q3 Loss, Lags Revenue Estimates

Alset EHome International

CooTek (Cayman) Inc - ADR

Future FinTech Group

Premarket stocks to watch under $5 gaining steam in the stock market today. The post Top Premarket Penny Stocks To Watch In The Stock Market Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Top Premarket Penny Stocks To Watch In The Stock Market Today

- Positive Phase 3 data in 2nd/3rd line NSCLC (Dublin-3): Superior efficacy benefit in plinabulin and docetaxel combination in overall survival, 2-year and 3-year OS rate, PFS, ORR, and significant reduction of grade 4 neutropenia vs. docetaxel alone

BeyondSpring Announces Third Quarter 2021 Financial Results and Provides a Corporate Update

BeyondSpring Inc (NASDAQ: BYSI) announced new data highlighting the mechanism of action of plinabulin in preventing chemotherapy-induced neutropenia (CIN) at the American Society of Hematology (ASH) Annual Meeting and Exposition.  The comparison was made between cancer patients receiving plinabulin 40 mg (n=228) or not receiving plinabulin (n=172) and with all patients receiving myelosuppressive chemotherapy.

BeyondSpring's New Plinabulin Data Shows Fast Onset In Preventing Chemo-Induced Neutropenia

NEW YORK, Dec. 15, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Pharmaceuticals (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global pharmaceutical company focused on the development of cancer therapeutics, today announced new data highlighting the mechanism of action of plinabulin in the prevention of chemotherapy-induced neutropenia (CIN) at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition, held virtually and in person in Atlanta, Georgia from December 11-14, 2021. The data demonstrate that adding plinabulin to a myelosuppressive regimen rapidly reversed (within 24 hours) neutropenia and leukopenia in the PROTECTIVE-1 and -2 clinical studies by protecting progenitor stem cells in the bone marrow.

BeyondSpring Pharmaceuticals Announces New Clinical Data Confirming Plinabulin's Fast Onset Mechanism of Action in the Prevention of Chemotherapy-Induced Neutropenia at the 63rd ASH Annual Meeting and Exposition

NEW YORK, Dec. 13, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of BeyondSpring Inc. ("BeyondSpring" or the "Company") (NASDAQ: BYSI). Such investors are advised to contact Robert S.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors BeyondSpring Inc. - BYSI

NEW YORK, Dec. 10, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Pharmaceuticals (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global pharmaceutical company focused on the development of cancer therapeutics, today announced the presentation of additional analyses from the Phase 3 portion of the PROTECTIVE-2 trial evaluating the combination of plinabulin and pegfilgrastim for the prevention of chemotherapy-induced neutropenia (CIN) in breast cancer patients at the 2021 San Antonio Breast Cancer Symposium (SABCS), held both live and virtually from December 7-10, 2021.

BeyondSpring Pharmaceuticals Announces Analysis of New Data on the Plinabulin/Pegfilgrastim Combination in Breast Cancer at the 2021 San Antonio Breast Cancer Symposium

Bluejay Diagnostics

Bit Brother Ltd

Invacare

NuZee, Inc.

OPKO Health

PetVivo Holdings

Petros Pharmaceuticals

Ring Energy

Spectrum Pharma

Looking for potential short squeeze penny stocks? Start by looking at short interest The post Best Penny Stocks To Buy Now?

Best Penny Stocks To Buy Now? 10 Short Squeeze Stocks To Watch

Short squeeze penny stocks to watch right now. The post Penny Stocks To Buy For A Short Squeeze?

Penny Stocks To Buy For A Short Squeeze? 5 To Watch Now

Atlanta, Georgia--(Newsfile Corp. - December 2, 2021) -  Holzer & Holzer, LLC is investigating whether BeyondSpring, Inc. ("BeyondSpring" or the "Company") (NASDAQ: BYSI) complied with federal securities laws. On December 1, 2021, BeyondSpring announced that it received a Complete Response Letter ("CRL") from the U.S. Food and Drug Administration ("FDA") for the Company's New Drug Application ("NDA") and that in the CRL the FDA indicated it cannot approve the Company's NDA in its current form....

SHAREHOLDER ALERT: Investigation of BeyondSpring, Inc. Announced by Holzer & Holzer, LLC

BeyondSpring Inc (NASDAQ: BYSI) is trading significantly lower Wednesday after the company announced it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for the plinabulin NDA for prevention of chemotherapy-induced neutropenia. The FDA issued the CRL to indicate that they have completed their review of the application and have determined that it cannot be approved in its current form.

Why BeyondSpring Shares Are Diving Today

The stock price of BeyondSpring Inc (NASDAQ: BYSI) fell by over 55% during intraday trading today. This is why it happened.

BeyondSpring (BYSI) Stock: Why The Price Substantially Fell Today

BeyondSpring is falling hard after the FDA turned down a once-promising drug candidate. Here's why you shouldn't write off BYSI stock.

BYSI Stock Alert: Bad News From the FDA Has BeyondSpring Tanking Today

The FDA has issued a Complete Response Letter to BeyondSpring Pharmaceuticals Inc's (NASDAQ: BYSI) marketing application seeking approval for plinabulin to prevent chemotherapy-induced neutropenia (CIN). The application covers plinabulin in combination with granulocyte colony-stimulating factor (G-CSF).

BeyondSpring Shares Crater After FDA Rejects Plinabulin Application

BeyondSpring Inc. BYSI, -1.84% said Wednesday that it has received a complete response letter (CRL) from the U.S. Food and Drug Administration, saying the biopharmaceutical company's new drug application (NDA) for its treatment for chemotherapy-induced neutropenia (CIN) "cannot be approved in its present form." The stock, which was up 5.7% prior to a trading halt for new, is set to resume trading at 8:30 a.m.

BeyondSpring's NDA for CIN treatment 'cannot be approved' in current form, FDA says

NEW YORK, Nov. 24, 2021 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global pharmaceutical company focused on the development of cancer therapeutics, today announced that management will participate in a Fireside Chat and host one-on-one investor meetings during the 4th Annual Evercore ISI HealthCONx Conference, taking place November 30-December 2, 2021. Details for the Fireside Chat can be found below:

BeyondSpring Pharmaceuticals to Present at the 4th Annual Evercore ISI HealthCONx Conference

Today, we look back in on a small oncology company called BeyondSpring for the first time since early this year. The stock quadrupled in August on good trial results but has fallen back 40% since then on some doubts around the data.

Circling Back On BeyondSpring

Allakos Inc

Deciphera Pharmaceuticals

These drugmakers have big events that should occur before the end of 2021.

3 Biotech Stocks With Huge Catalysts Incoming

—The study is conducted by the Big Ten Cancer Research Consortium in up to 26 patients across 7 states in the U.S.

BeyondSpring Announces First Patient Treated in Phase 2 Study with Plinabulin Combined with Nivolumab + Ipilimumab in Patients in 3rd Line Recurrent Small-Cell Lung Cancer Patients Who Failed Checkpoint Inhibitors

News for BeyondSpring Stock (BYSI)